Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

The WHO 2016 AML-MRC designation applies to AML patients (pts) with a history of myelodysplastic syndrome (MDS) or MDS/myeloproliferative neoplasm, a MDS-related cytogenetic abnormality, or multilineage dysplasia in>50% of ≥2 cell lineages in the absence of NPM1 or biallelic CEBPA mutations. AML-MRC pts typically have a poor prognosis after induction chemotherapy. CPX-351 (Vyxeos®; daunorubicin and cytarabine liposome for injection), a dual-drug liposomal encapsulation of cytarabine [C] and daunorubicin [D] at a sy nergistic ratio, is approved by the FDA and EMA for the treatment of adults with newly diagnosed therapy-related AML or AML-MRC.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Daniel H. Ryan, Laura F. Newell, Ellen K. Ritchie, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Gary J. Schiller, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes Tags: 9 Source Type: research